TP53 and acute myeloid leukemia: In a survival analysis of gene mutations present in more than 10% of patients with AML, a statistically significant difference was detected in median OS based on only FLT3-ITD and TP53 mutations (p < 0.05; median OS 7.2 and 2.3 months with mutation vs. 11.7 and 10.3 months without mutation, respectively).